US bans imports from 3 Chinese biotech companies over forced labor allegations

US bans imports from 3 Chinese biotech companies over forced labor allegations The Biden administration announced on Tuesday that it will block the import of certain biological products and related services from three Chinese biotech firms – BGI Group, its subsidiary Complete Genomics and a third, Zhejiang Tianyuan Biotechnology – on grounds of alleged links to forced‑labour practices in Xinjiang. The move, announced by the Office of the United States Trade Representative (USTR), follows a decade‑long campaign by US officials to curb what they describe as human‑rights abuses in the region, and marks the first time the ban has been applied to the biotech sector rather than the more common textiles or electronics. In a detailed statement, the USTR said the companies “benefit from, and are complicit in, the use of forced labour in Xinjiang” and that their products – including DNA sequencing kits, gene‑editing reagents and diagnostic reagents – “pose a risk of being produced using forced labour”..

The ban will be enforced under Section 301 of the Trade Act, which allows the president to impose trade restrictions where foreign practices threaten US economic interests. The administration gave companies a 30‑day window to cease any shipments to the United States before the prohibitions take effect. BGI, the world’s largest genomics services provider, has been a frequent target of US scrutiny since 2019, when it was added to a list of entities suspected of facilitating surveillance of Uighur Muslims..

The firm has repeatedly denied any involvement in forced‑labour schemes, insisting that its supply chain complies with international standards and that it conducts regular audits of its vendors. In response to the new ban, BGI’s chief executive, Chen Zhenqiu, called the decision “unjustified and politically motivated”, urging the US to “re‑evaluate the evidence” and to engage in dialogue rather than punitive measures. Complete Genomics, a US‑based subsidiary of BGI that specialises in whole‑genome sequencing, was also named in the ban..

Although its operations are headquartered in California, the company’s core technology and many of its reagents are manufactured in China. Critics argue that this blurs the line between domestic and foreign production, making it harder for US labs to source compliant materials. The ban therefore threatens to disrupt ongoing research projects, from cancer genomics to pathogen surveillance, that rely on the company’s high‑throughput platforms..

Zhejiang Tianyuan Biotechnology, a smaller but rapidly growing firm, supplies reagents used in polymerase chain reaction (PCR) tests and other molecular diagnostics. Its inclusion in the restriction list is significant because the firm has secured contracts with several American clinical laboratories, especially during the COVID‑19 pandemic, when demand for reliable test kits surged. Health‑care providers have warned that a sudden loss of supply could force laboratories to seek alternative vendors, potentially delaying diagnostic turnaround times and increasing costs for patients..

The ban arrives amid a broader US strategy to pressure China over human‑rights violations. In recent months, Washington has tightened export controls on advanced semiconductor equipment and semiconductor manufacturing software, while also expanding the scope of the “Entity List” to include more Chinese firms. The new biotech restriction is the first to target the life‑sciences sector directly, signalling that Washington sees the supply chain for genetic material as strategically sensitive and vulnerable to abuse..

Industry analysts say the decision could have ripple effects beyond the immediate ban. “Biotech is a globally interconnected field; a restriction on a few key suppliers can reverberate through research institutions, pharmaceutical development pipelines and even public‑health surveillance programmes,” said Dr Sophie Patel, senior fellow at the Center for Global Trade Policy. “If the US continues to expand its forced‑labour list, companies may need to rethink how they source critical reagents, potentially accelerating a shift toward domestic production or diversification to other regions such as Europe or Southeast Asia.” The Chinese government, through its Ministry of Commerce, denounced the ban as “baseless and discriminatory”, urging the United States to stop “politicising trade and undermining the normal order of international economic relations”..

Beijing also warned of “necessary countermeasures”, a phrase commonly used to signal possible retaliatory steps, though it stopped short of specifying any concrete actions. The Chinese foreign ministry’s spokesperson added that the allegations of forced labour in Xinjiang have been “repeatedly debunked by independent investigations”. lawmakers from both parties have expressed support for the administration’s move..

Representative Jim McGovern (D‑MA), a longtime advocate for Uighur rights, called the ban “a decisive step in holding abusers accountable”. Meanwhile, Senator Marco Rubio (R‑FL) urged the administration to expand the list to include more firms that “profit from a system that exploits vulnerable populations”. However, some bipartisan voices cautioned against a blanket approach that could impair scientific collaboration..

“We must protect human rights, but also safeguard the flow of scientific knowledge that benefits global health,” said Representative Ro Khanna (D‑CA). Legal experts note that the ban could face challenges under World Trade Organization (WTO) rules, which prohibit discriminatory treatment of foreign goods unless justified by public policy exceptions. The United States will need to provide sufficient evidence of forced‑labour involvement to withstand any potential dispute settlement..

In the past, similar US measures targeting cotton and tomato products from Xinjiang have been contested by China at the WTO, though outcomes remain unresolved. The biotech sector’s technical complexity may further complicate any legal arguments. For US research institutions, the immediate priority is to secure alternative sources for the affected reagents..

The National Institutes of Health.